Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
12.75    -0.25 (-1.92%)
Bid:
12.00
Ask:
13.50
Spread: 1.50 (12.50%)
Market Cap: £15.94m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

25 Jun 2007 11:36

Fabian Romania Property Fund Ltd25 June 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or "Fabian") Fabian Romania acquires a 50 per cent. interest in a residential developmentsite to build 250 apartments in Timisoara for €4.7 million Fabian Romania is pleased to announce that it has purchased 50 per cent. of adevelopment company owning a 1.1 hectare site in north Timisoara. The equityconsideration amounts to approximately €1 million. The land area totals approximately 11,000 square metres and has urban zoningapproval to build over 250 apartments (subject to building permits) comprisingover 30,000 square metres of residential development space. Coltex, theco-shareholder holding the other 50% interest, has entered into a partnershipagreement with Fabian. Coltex will also be the development manager and has aknown track record, having developed and sold the successful Banu Antonachebuilding to Fabian in late 2005. Timisoara is Romania's third largest city with a population of over 300,000 andis located in the West close to the Hungarian border. The Investment Managerbelieves the city has attractive characteristics for supply of modernresidential apartments. The purchase price for the land including acquisition expenses was €4.7 million.This equates to around €427 per square metre for the land and €157 per builtsquare metre overground, assuming 30,000 square metres. The development companyhas already secured and fully drawdown on a land finance facility from BancaRomaneasca for €3.6 million. Including near term working capital needs, thisleaves an initial net equity requirement of approximately €1 million for Fabian. Responsible for the acquisition, Mark Owen, Property Director of Fabian Capital,Fabian Romania's investment adviser said: "This is the first investment for Fabian outside Bucharest and our secondresidential scheme. The purchase price for the land is extremely attractiverelative to comparable plots in Bucharest. We are also happy to have enteredinto a new partnership with Coltex for this development. Whilst it is clearTimisoara is in its infancy within the development process, strong indicationsexist that the residential sector is very undersupplied and that demand existsfor good, mid market apartments against a background of increasing prices." For Comments: Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLPJames Lewis +44 20 7936 3000 Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Jan 20257:00 amRNSOptiMAL R&D Update
4th Dec 202411:31 amRNSApproval of Grant Funding Application
19th Nov 20247:00 amRNSHalf-year Report
16th Oct 20241:23 pmRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSIssue of shares to non-executive directors
8th Oct 202412:32 pmRNSResult of AGM
8th Oct 20247:00 amRNSAGM statement and trading update
2nd Oct 20247:00 amRNSBlock admission six monthly return
12th Sep 20249:54 amRNSNotice of AGM
9th Sep 202412:35 pmRNSDirector/PDMR Shareholding
5th Sep 202412:15 pmRNSDirector/PDMR Shareholding
5th Sep 20247:00 amRNSFinal Results
22nd Jul 202412:54 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSTrading update
23rd May 20247:00 amRNSNew contract with existing client
2nd May 20247:00 amRNSInvestor presentation
30th Apr 20247:00 amRNSYear-end trading statement
16th Apr 20247:00 amRNSChange of auditor
15th Apr 20247:00 amRNSContract to develop a bespoke OptiPhage library
2nd Apr 20242:34 pmRNSBlock admission six monthly return
28th Mar 20245:00 pmRNSTotal Voting Rights
11th Mar 20243:04 pmRNSHolding(s) in Company
11th Mar 20249:10 amRNSHolding(s) in Company
8th Mar 20243:09 pmRNSHolding(s) in Company
5th Mar 202410:40 amRNSResult of General Meeting and Total Voting Rights
29th Feb 20245:00 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSFirst purchase order under MSA
14th Feb 20247:15 amRNSGrant of options and issue of shares to directors
14th Feb 20247:00 amRNSPlacing to raise £1,375,000
6th Feb 20247:00 amRNSFollow-on project award and R&D update
1st Feb 20247:00 amRNSHMRC R&D tax credit
4th Dec 202312:26 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSHalf-year Report
28th Nov 20237:00 amRNSOptiMAL collaboration agreement
9th Nov 20237:00 amRNSHalf year trading update
27th Oct 202311:57 amRNSResult of AGM
4th Oct 20232:45 pmRNSBlock admission six monthly return
29th Sep 20237:00 amRNSFinal Results
29th Aug 20237:00 amRNSUpdate on AI/ML-Ab service offering
24th Aug 20237:00 amRNSAppointment of interim CFO
21st Aug 20237:00 amRNSUpdate on AI/ML-Ab™ antibody discovery service
14th Aug 20237:00 amRNSUpdate on restructure and cost savings
30th Jun 20235:00 pmRNSTotal Voting Rights
16th Jun 202310:09 amRNSHolding(s) in Company
15th Jun 20239:45 amRNSHolding(s) in Company
13th Jun 20232:44 pmRNSHolding(s) in Company
12th Jun 20233:34 pmRNSHolding(s) in Company
12th Jun 202311:02 amRNSDirector/PDMR Shareholding
8th Jun 202310:39 amRNSResult of GM and total voting rights
31st May 20235:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.